Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Selegiline as Initial Treatment of De Novo Parkinsonian Patients
Neurol 42:339-343, Myllyla,V.V.,et al, 1992
The Antiparkinson Efficacy of Deprenyl Derives from Transient Improvement that is Likely to be Symptomatic
Ann Neurol 32:795-798, Schulzer,M.,et al, 1992
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Science 245:519-522, Tetrud,J.W.&Langston,W., 1989
Current Theories on the Cause of Parkinson's Disease
JNNP Suppl (June) 52:13-17989., Langston,J.W., 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
Phenelzine Toxicity Responsive to Dantrolene
Neurol 37:865-867, Verrilli,M.R.,et al, 1987
MPTP:A Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease, The 1985 George Cotzias Lecture
Neurol 36:250-258, Snyder,S.H.&D'Amato,R.J., 1986
Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977